Drug Compounding With Bulk Substances: FDA Offers Interim Policies
By Zachary Brennan -
Published 16 January 2017
The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency does not intend to take action against certain outsourcing facilities and compounded drugs.
Categories: News, US, FDA, Active pharmaceutical ingredients, Crisis management, Drugs, Quality
Tags: drug compounding, compounded drugs, 503A, 503B, FDA interim policy
In FDA Effort to Strengthen Regulation of Compounded Drugs, Protections and Profits Intersect
By Alexander Gaffney, RAC -
Published 04 September 2014
A new law meant to protect consumers from unsafe pharmaceutical compounding practices is drawing interest from pharmaceutical companies, who are petitioning the US Food and Drug Administration (FDA) to add some of their products to a new list of restricted drugs that could protect patients from deficient drugs—and likely companies from compounded competition as well.
Categories: News, US, CDER, Drugs, Manufacturing, Regulatory strategy
Tags: 503A 503B, Pharmaceutical Compounding, Compounding, DQSA, Drug Quality and Security Act, Difficult-to-Compound List